Founded in 2014, Saphetor is a precision medicine company at the cutting edge of genome-scale analysis based on Next Generation Sequencing (NGS). Capitalizing on the emerging trend in NGS to use large “panels” of genes, exomes, or whole genomes, Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment.
25.07.2024
Saphetor Obtains European CE Mark (startupticker.ch)
30.10.2020
Saphetor and Roche join forces (startupticker.ch)
11.01.2018
New startup investments by the Go Beyond community (startupticker.ch)
04.08.2017
Saphetor’s platform used to facilitate precision oncology treatments (startupticker.ch)
04.08.2017
Saphetor?s platform used to facilitate precision oncology treatments (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Website:
saphetor.com/
Headquarter:
Lausanne
Foundation Date:
March 2014
Technology: